2.68
Immunitybio Inc stock is traded at $2.68, with a volume of 7.92M.
It is up +3.33% in the last 24 hours and up +7.04% over the past month.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.
See More
Previous Close:
$2.60
Open:
$2.61
24h Volume:
7.92M
Relative Volume:
1.04
Market Cap:
$2.37B
Revenue:
$1.31M
Net Income/Loss:
$-597.65M
P/E Ratio:
-2.7629
EPS:
-0.97
Net Cash Flow:
$-425.62M
1W Performance:
+6.19%
1M Performance:
+7.04%
6M Performance:
-46.69%
1Y Performance:
-59.36%
Immunitybio Inc Stock (IBRX) Company Profile
Name
Immunitybio Inc
Sector
Industry
Phone
(844) 696-5235
Address
3530 JOHN HOPKINS COURT, SAN DIEGO
Compare IBRX with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
IBRX
Immunitybio Inc
|
2.685 | 2.37B | 1.31M | -597.65M | -425.62M | -0.97 |
![]()
ONC
Beone Medicines Ltd Adr
|
247.45 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
444.39 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.42 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
491.45 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
May-20-25 | Upgrade | Piper Sandler | Neutral → Overweight |
Mar-06-25 | Initiated | H.C. Wainwright | Buy |
Jan-10-25 | Initiated | BTIG Research | Buy |
May-12-23 | Downgrade | Piper Sandler | Overweight → Neutral |
Aug-03-22 | Initiated | Jefferies | Buy |
Immunitybio Inc Stock (IBRX) Latest News
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, - openPR.com
Advanced Pancreatic Cancer Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte, AbbVie, Ability Pharma, AB Science, AstraZeneca, Eleison Pharma, ImmunityBio - The Globe and Mail
Why ImmunityBio, Inc. (IBRX) Surged On Thursday - MSN
ImmunityBio: BioShield Platform Expands to Middle East and Other Important Updates - TradingView
ImmunityBio: Analyst Reaffirms $30 Price Target and Other Important Updates - TradingView
ImmunityBio (IBRX) Stock Rating and Price Target Update | IBRX Stock News - GuruFocus
Cancer BioShield Platform Comes to Saudi Arabia and the Middle East - Vax-Before-Travel
ImmunityBio, Saudi Arabia’s Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding to Launch Cancer BioShield™ Platform in the Middle East - BioSpace
ImmunityBio Signs Agreement to Launch BioShield in Saudi Arabia, Middle East - marketscreener.com
Immunitybio, Inc. Signs Strategic Memorandum of Understanding to Launch Cancer Bioshield Platform in the Middle East - marketscreener.com
ImmunityBio, Saudi Arabia's Ministry of Investment, KFSHRC, and KAIMRC Sign Strategic Memorandum of Understanding - marketscreener.com
ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle E - GuruFocus
ImmunityBio (IBRX) Expands Cancer Treatment Platform to Middle East | IBRX Stock News - GuruFocus
Natural Killer (NK)-Cell Lymphoma Market to Expand - openPR.com
Natural Killer (NK)-Cell Lymphoma Market to Expand Significantly by 2032, States DelveInsight Report | Innate Pharma, Nektar Therapeutics, ImmunityBio, CytoVac, Celularity - The Globe and Mail
ImmunityBio Board Settles Shareholders’ Cancer Therapy Lawsuit - Bloomberg Law News
Why ImmunityBio, Inc. (IBRX) Crashed Today - MSN
Piper Sandler Upgrades ImmunityBio (IBRX) to Overweight, Lifts PT - Insider Monkey
Piper Sandler Upgrades ImmunityBio (NASDAQ:IBRX) to Overweight - Defense World
Jim Cramer Notes ImmunityBio (IBRX) Has “Been Losing Money Forever” - Insider Monkey
Piper Sandler Upgrades ImmunityBio (IBRX) - Nasdaq
10 Firms Drenched in Red Today - Insider Monkey
Jim Cramer’s Recent Thoughts on These 15 Stocks - Insider Monkey
Piper Sandler raises ImmunityBio stock rating, target to $5 By Investing.com - Investing.com Nigeria
ImmunityBio (IBRX) Upgraded to Overweight by Piper Sandler - GuruFocus
Why ImmunityBio, Inc. (IBRX) Surged Last Week - Insider Monkey
ImmunityBio upgraded to Overweight at Piper Sandler on Anktiva success - Seeking Alpha
ImmunityBio (IBRX) Receives Analyst Upgrade and Price Target Increase | IBRX Stock News - GuruFocus
Piper Sandler raises ImmunityBio stock rating, target to $5 - Investing.com
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Ca - GuruFocus
ImmunityBio (IBRX) Receives Upgrade with Promising Outlook on Cancer Therapies | IBRX Stock News - GuruFocus
Why ImmunityBio’s Stock is on the Rise - TipRanks
ImmunityBio (IBRX) Receives Upgrade from Piper Sandler | IBRX Stock News - GuruFocus
Dimensional Fund Advisors LP Boosts Holdings in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
FDA Delivers Blow to ImmunityBio - Los Angeles Business Journal
Mercer Global Advisors Inc. ADV Purchases 8,359 Shares of ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio, Inc. (NASDAQ:IBRX) Holdings Decreased by Price T Rowe Associates Inc. MD - Defense World
Biotechs need a new guidebook to parse FDA messaging: a Perspective - BioCentury
Q2 Earnings Forecast for ImmunityBio Issued By HC Wainwright - Defense World
ImmunityBio (IBRX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Earnings Update: Here's Why Analysts Just Lifted Their ImmunityBio, Inc. (NASDAQ:IBRX) Price Target To US$13.00 - Yahoo
HC Wainwright Reaffirms Buy Rating for ImmunityBio (NASDAQ:IBRX) - Defense World
Raymond James Financial Inc. Takes $172,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
BTIG maintains ImmunityBio stock Buy rating, $6 target By Investing.com - Investing.com Nigeria
BTIG maintains ImmunityBio stock Buy rating, $6 target - Investing.com
Why ImmunityBio Stock is Gaining Momentum - TipRanks
Decoding ImmunityBio Inc (IBRX): A Strategic SWOT Insight - GuruFocus
Hsbc Holdings PLC Takes $44,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX) - Defense World
ImmunityBio Sees Revenue Surge Amid Strong Sales Momentum - TipRanks
Why ImmunityBio, Inc. (IBRX) Soared Today - MSN
ImmunityBio: Q1 Earnings Snapshot - MySA
Immunitybio Inc Stock (IBRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immunitybio Inc Stock (IBRX) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
SOON-SHIONG PATRICK | See remarks |
Feb 22 '25 |
Option Exercise |
0.00 |
114,329 |
0 |
29,588,261 |
Sachs David C. | Chief Financial Officer |
Feb 22 '25 |
Option Exercise |
0.00 |
40,650 |
0 |
241,480 |
Adcock Richard | CEO & President |
Feb 22 '25 |
Option Exercise |
0.00 |
152,439 |
0 |
412,585 |
Simon Barry J. | Director |
Feb 22 '25 |
Option Exercise |
0.00 |
15,243 |
0 |
3,249,024 |
Simon Barry J. | Director |
Jan 22 '25 |
Option Exercise |
2.00 |
110,020 |
219,864 |
3,233,781 |
Adcock Richard | CEO & President |
Dec 31 '24 |
Option Exercise |
0.00 |
34,483 |
0 |
277,621 |
Sachs David C. | Chief Financial Officer |
Dec 31 '24 |
Option Exercise |
0.00 |
30,397 |
0 |
216,235 |
LAUER REGAN J | Chief Accounting Officer |
Dec 15 '24 |
Option Exercise |
0.00 |
21,031 |
0 |
115,365 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):